RecruitingPhase 3NCT07495852

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Sponsor

Glaukos Corporation

Enrollment

510 participants

Start Date

Feb 17, 2026

Study Type

INTERVENTIONAL

Conditions

Glaucoma

Summary

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Eligibility

Min Age: 18 Years

Inclusion Criteria1

Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye

Exclusion Criteria3

Prior incisional glaucoma surgery in the study eye
Prior argon laser trabeculoplasty (ALT) in the study eye
Prior minimally invasive glaucoma (MIGS) surgery in the study eye

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGen 2 Travoprost Intracameral Implant

Travoprost

DRUGTimolol eye drops 0.5%

Timolol 0.5%

PROCEDURESham Procedure

Sham implant administration

OTHERplacebo eye drops

Artificial Tears

Locations(1)

Glaukos Investigative Site

Dothan, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07495852

Related Trials

Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension

NCT075881521 location

A Study Evaluating the Safety and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma

NCT070092365 locations